Published in final edited form as:

Am J Obstet Gynecol. 2017 January ; 216(1): 1–9. doi:10.1016/j.ajog.2016.08.008.

Sexually Transmitted Diseases and Infertility

Ms. Danielle G. TSEVAT, BA¹, Harold C. WIESENFELD, MD², Caitlin Parks, MD¹, and Jeffrey F. PEIPERT, MD, PhD³

¹Washington University in St. Louis School of Medicine, Division of Clinical Research Department of Obstetrics and Gynecology

²Division of General Gynecology, Department of Obstetrics and Gynecology; University of Pittsburgh School of Medicine; Pittsburgh, PA

³Department of Obstetrics and Gynecology; Indiana University School of Medicine; Indianapolis, IN

Abstract

Female infertility, including tubal factor infertility, is a major public health concern worldwide. Most cases of tubal factor infertility are attributable to untreated sexually transmitted diseases that ascend along the reproductive tract and are capable of causing tubal inflammation, damage, and scarring. Evidence has consistently demonstrated the effects of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* as pathogenic bacteria involved in reproductive tract morbidities including tubal factor infertility and pelvic inflammatory disease. There is limited evidence in the medical literature that other sexually transmitted organisms, including *Mycoplasma genitalium*, *Trichomonas vaginalis*, and other microorganisms within the vaginal microbiome may be important factors involved in the pathology of infertility. Further investigation into the vaginal microbiome and other potential pathogens is necessary in order to identify preventable causes of tubal factor infertility. Improved clinical screening and prevention of ascending infection may provide a solution to the persistent burden of infertility.

Overview

Infertility, which is defined as the inability to conceive after 12 months or longer of regular unprotected sexual intercourse, is a common public health concern worldwide. Globally, 9% of reproductive-aged women, including nearly 1.5 million women in the United States, are infertile (1, 2). The burden of infertility is inordinately higher among women in developing

Correspondence (no reprints): Jeffrey F. Peipert, MD, PhD, Clarence E. Ehrlich Professor and Chair, Indiana University School of Medicine, Department of Obstetrics & Gynecology, 550 N. University Blvd., UH 2440, Indianapolis, IN 46202, jpeipert@iu.edu, 317-944-8609.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Other authors report no financial conflicts in past 12 months.

Condensation

There is evidence that *Chlamydia trachomatis* and *Neisseria gonorrhoeae* can cause tubal factor infertility; however, additional pathogens also may be important factors.

countries; in some of regions of South and Central Asia, sub-Saharan and Northern Africa, the Middle East, and Eastern Europe, infertility rates can reach up to 30% in reproductive-aged women (3). The inability to conceive not only creates a considerable cost burden for patients and the healthcare system but is also a major psychological stressor for millions of couples (4). In several areas of the world, especially in low- and middle-income countries where having biological children is highly valued and expected of couples, involuntary infertility can lead to stigmatization, economic deprivation, social isolation and loss of status, public shame and humiliation, and in some cases, violence (5, 6). Female infertility may be attributed to a number of factors, typically divided into endocrine, vaginal, cervical, uterine, tubal, and pelvic-peritoneal factors, and although estimates vary, approximately 15-30% of cases still remain unexplained (7). Further insight into the causes of infertility is necessary to help alleviate this multifactorial burden on society.

Tubal factor infertility (TFI) ranks among the most common causes of infertility, accounting for 30% of female infertility in the United States and is even more prevalent in certain communities (8). Paralleling the aforementioned global infertility disparity, TFI is disproportionately common in women in developing countries; for example, it has been shown to account for over 85% of female infertility cases in regions of sub-Saharan Africa compared to 33% of cases worldwide (3). Most cases of TFI are due to salpingitis, an inflammation of the epithelial surfaces of the fallopian tubes, and subsequent pelvic-peritoneal adhesions, both of which are mostly caused by previous or persistent infections (9, 10). Bacteria ascend along mucosal surfaces from the cervix to the endometrium and ultimately to the fallopian tubes. This causal pathway presents itself clinically as acute pelvic inflammatory disease (PID), which in turn is strongly associated with subsequent TFI. In fact, approximately 15% of women with PID develop TFI, and the number of episodes of PID a woman experiences is directly proportional to her risk of infertility (11, 12). However, the majority of women with TFI do not have a history of clinically-diagnosed acute PID, but rather develop asymptomatic or minimally-symptomatic salpingitis as a result of upper genital tract infection (9, 13). Examining the effect of those infections, particularly those that occur in the absence of clinically-evident PID, is critical to understanding TFI.

Several sexually transmitted diseases (STDs), including *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, have been widely studied to understand their role in salpingitis and infertility. Additionally, several other pathogens such as *Mycoplasma genitalium*, *Trichomonas vaginalis*, and other microorganisms within the vaginal microbiome may also play roles in tubal damage and other potential causes of infertility. Still, data suggest that not all infections yield the same long-term sequelae. The roles of different STD pathogens, co-infections, and interactions with host characteristics, including their individual vaginal microbiome, may all affect a woman's subsequent ability to conceive. While screening and treatment efforts for *C. trachomatis* and *N. gonorrhoeae* have been developed to reduce the incidence of PID and subsequent TFI, additional data is needed to determine the role of other potential pathogens and whether early detection can prevent tubal damage. In this paper, we discuss the pathogens *C. trachomatis*, *N. gonorrhoeae*, *M. genitalium*, *T. vaginalis*, and other potential organisms that may affect female fertility, and we address the clinical importance of screening and preventing the spread of those infections.

Methodology

We conducted a comprehensive literature search to identify articles by using the electronic databases Medline, Embase, Web of Science, and CINAHL, in addition to scrutinizing references of identified articles. Within each database, we combined the term “female infertility” with four different infection terms: “*Chlamydia trachomatis*,” “*Neisseria gonorrhoeae*,” “*Mycoplasma genitalium*,” and “*Trichomonas vaginalis*.” Within the Medline database, we refined the search by excluding the MeSH headings unrelated to female infertility and at least one of the four organisms. Within the Embase search, we used Emtree to identify terms, and used both “female infertility” and “uterine tube occlusion” as focused search terms to combine with each infection. We filtered results to only include articles published in English after 1975 until April 2016. Additional relevant articles were identified from bibliographies and by the recommendation of medical experts. The inclusion of the articles used in the analysis was based on quality of the study and relevance to this review: studies were excluded if they were conducted with few participants, had no comparison group, or constituted of case reports. Studies that did not report sufficient data to determine the association with female infertility or reproductive morbidities were excluded for lack of relevance to the topic of review.

Chlamydia trachomatis* and *Neisseria gonorrhoeae

C. trachomatis and *N. gonorrhoeae* have been extensively shown to be associated with infertility, particularly by causing tubal inflammation. In fact, early speculation regarding the effect of *N. gonorrhoeae* on female fertility dates back to the 1870s, when the German-born gynecologist Emil Noeggarath published his revolutionary claims about gonorrhea as a clinical condition in his book *Latent Gonorrhoea in the Female Sex* (14). Though he may have widely overestimated its repercussions (postulating that gonorrhea causes 90% of female infertility), his theories eventually sparked the initiation of further investigations (15). When the bacterium *N. gonorrhoeae* was finally isolated, Noeggarath's controversial claims regarding the persistence of this “venereal poison” in the reproductive organs and its pathologic consequences were reexamined (16). Studies conducted more than a century later have since demonstrated the impact of *C. trachomatis* and *N. gonorrhoeae* on subsequent infertility.

Chlamydia trachomatis, the most common reportable disease in the United States, affects nearly 1.5 million US citizens annually (17). Unfortunately, however, because *C. trachomatis* infections are asymptomatic in most women (18, 19), infections are often unnoticed, untreated, and under-reported. For almost 40 years, evidence has shown that untreated ascending *C. trachomatis* infection can lead to irrevocable damage in the fallopian tubes including proximal and distal tubal occlusions leading to infertility (39). The increased amount of heat shock protein (hsp60) synthesized by *C. trachomatis* induces a proinflammatory immune response in the human fallopian tube epithelia, resulting in scarring and tubal occlusion (9, 20, 21). A number of seroepidemiological studies have examined the prevalence of antibodies to *C. trachomatis* and chlamydial hsp60 in women with laparoscopically- or hysterosalpingographically-confirmed fallopian tube damage and ectopic pregnancies (22-28), indicating that history of *C. trachomatis* infection is associated

with a significantly increased risk of tubal infertility in women, regardless of the infection invoking clinical symptoms (20, 25, 29-32). Extensive research has also shown that *C. trachomatis* infection can cause PID, which often precedes infertility in women. Today, *C. trachomatis* accounts for approximately 50% of cases of acute PID in developed countries (33). Among PID patients, those with prior *C. trachomatis* infection have been shown to be more likely to experience subsequent infertility than those without a history of *C. trachomatis* infection (32-35).

While *C. trachomatis* seropositivity has long been shown to influence fallopian tube patency (36), the use of a newer, more sensitive and specific anti-CT assay by Geisler and coworkers anti-CT assay has only recently been shown to hold promise as a measure of tubal function (37, 38). In one cohort study of 1,250 infertile women with documented tubal patency undergoing fertility treatment, *C. trachomatis* seropositivity using the antibody subclasses IgG1 and IgG3 was tested (39). Results showed that of these two antibody subclasses tested, seropositivity to *C. trachomatis* based on IgG3 detection was a strong predictor of both failure to conceive and ectopic pregnancy outcomes. Because IgG3 has been shown to be involved in early inflammatory response to infection (40), the detection of IgG3 in these women may reflect that either *C. trachomatis* infection has recently cleared or indicate a persisting infection, contributing to fallopian tube damage while perhaps not yet leading to blockage of the fallopian tubes (39).

In another study of subfertile women with no visible tubal pathology, chlamydial antibody testing was associated with a 33% lower spontaneous pregnancy rate than those without chlamydial antibodies (39, 41). Coppus and colleagues suggest that these low pregnancy rates may not only be caused by the known mechanism of chronic inflammatory response causing fallopian tube damage; persistent *C. trachomatis* infections have also been shown to elicit an autoimmune response to human heat shock proteins, which may elevate the risk for impaired embryo development and implantation (41-43). Chlamydial antibody testing may therefore continue to become a valuable predictor of not only tubal patency, but also of ectopic pregnancy, intrauterine insemination failure, and embryo and pregnancy wastage, independent of tubal damage.

Although less prevalent than *C. trachomatis* in the United States, gonorrhea is still the second most common reportable disease in the United States (17). *N. gonorrhoeae* infections are also often asymptomatic among women, but as Noeggarath suspected in the 1870s, the bacterium is capable of ascending to the upper genital tract and causing severe reproductive morbidities. In particular, *N. gonorrhoeae* attacks the epithelial cells of the fallopian tube, both initially by attaching to the nonciliated mucosal cells and by sloughing off ciliated mucosal cells (9). The resulting damage hinders the fallopian tubes' ability to transport the ovum for fertilization within the tubes and implantation in the uterus, thus ultimately elevating the risk of infertility and ectopic pregnancy.

Several seroepidemiological studies have demonstrated the pathogen's effects on fallopian tube damage and subsequent infertility (44-48). Throughout those studies, women with laparoscopically- and hysterosalpingographically-confirmed TFI have consistently been shown to have a significantly higher prevalence of serologically-confirmed *N. gonorrhoeae*

infection than women with normal fallopian tubes. Like chlamydial PID, gonococcal PID has been shown to be an important cause of fallopian tube damage, greatly increasing a woman's risk of TFI. Ten to 19% of women with cervical *N. gonorrhoeae* infections have clinical signs of acute PID (50) and in regions of the U.S. with high endemic rates of gonorrhea during the 1970s and 1980s, gonorrhea was found in more than 40-50% of patients with PID (51). In recent studies, the bacteria have been identified in approximately 20% of women diagnosed with acute PID, suggesting that *N. gonorrhoeae* is not as frequent a cause of acute PID as it had been in the past (52, 53). Still, the impact of both chlamydial and gonococcal infections on the fallopian tubes currently make these pathogens the most important known preventable causes of infertility, and improving screening programs for these prevalent and commonly asymptomatic pathogens may therefore make a critical impact in the prevention of tubal pathology and infertility.

Mycoplasma genitalium

While *N. gonorrhoeae* and *C. trachomatis* are known to be pathogens in salpingitis and tubal infertility, in many cases, neither organism is identified (52). *Mycoplasma genitalium*, a member of the *Mollicutes* class with the smallest known genome of any free-living organism (54), was discovered in 1981 when it was first isolated from men with non-gonococcal urethritis (55). After the development of nucleic acid amplification assays in the early 1990s facilitating its detection, *M. genitalium* has since been shown to be a common sexually transmitted organism. (56). In the United States in 2007, the prevalence of *M. genitalium* in young adults was 1%, placing it between *N. gonorrhoeae* (0.4%) and *C. trachomatis* (2.3%) infections, and it has been detected in 15-20% of high-risk, sexually active women in the United States (57-59).

Since its discovery, numerous studies demonstrate that *M. genitalium* is strongly associated with male urethritis. In an analysis of 34 studies published between 1993-2011 studying men with non-gonococcal urethritis, 13% of 7123 men tested positive for *M. genitalium*, and several studies have demonstrated that *M. genitalium* can cause persistent or recurrent urethritis (60). After the initial findings of *M. genitalium* demonstrating its effects in males, investigators soon began to look at its effects on the female reproductive tract. While there are fewer studies in women, *M. genitalium* has been investigated to evaluate its association with several morbidities in women, including cervicitis, urethritis, PID, ectopic pregnancy, and TFI (60).

Four serological studies have investigated the relationship between past *M. genitalium* infection in women and tubal infertility (23, 24, 61, 62). Two of those studies have demonstrated a significant correlation between presence of antibodies against *M. genitalium* and laparoscopically-confirmed TFI, independent of *C. trachomatis* seropositivity (23, 24). According to Svenstrup and colleagues, among women with TFI, 23% had antibodies to *C. trachomatis* and 17% to *M. genitalium*; whereas 15% and 4% of infertile women with normal fallopian tubes had antibodies to each, respectively (24). Though not quite as high as the prevalence of antibodies to *C. trachomatis*, prior *M. genitalium* infection is thought to be an independent risk factor for tubal factor infertility. In a similar study by Clausen and colleagues, serological analyses of women with TFI reinforced the finding that *M.*

genitalium is independently associated with tubal inflammation leading to infertility (23). A more recent study by Idahl and colleagues examined the association between *M. genitalium* antibodies and infertility in 239 women diagnosed with infertility of various causes, including laparoscopically- and hysterosalpingographically-confirmed TFI, compared to 244 fertile controls (61). The results indicate that *M. genitalium* serum antibodies are more common among women with all causes of infertility (5.4%) than in fertile controls (1.6%). Among the infertile women in that sample diagnosed specifically with TFI, 9.1% were seropositive for *M. genitalium* compared with 4.6% of the fertile controls, although the association between TFI and *M. genitalium* was not statistically significant after adjusting for *C. trachomatis* seropositivity (61).

Supporting evidence has shown an association between infection with *M. genitalium* at the time of infertility evaluation and laparoscopically-confirmed tubal infertility, rather than serologically investigating past infection history. In a study comparing infertile and fertile women by polymerase chain reaction testing of cervical samples, *M. genitalium* was detected more frequently in infertile women (19.6%) compared to fertile women (4.4%) (63). However, in the study by Svenstrup and colleagues that examined the relationship between *M. genitalium* seropositivity and TFI, none of the women had a cervical swab specimen indicating current *M. genitalium* infection, and only one was positive for *C. trachomatis* (24). There does not appear to be a role for screening for *M. genitalium* infection at the time of infertility evaluation.

Several other studies, though not directly addressing fertility rates, have investigated the effects that *M. genitalium* may have on tubal inflammation, damage, and occlusion. The mechanism by which *M. genitalium* may cause the tubal scarring that leads to infertility has been studied through several *in vitro* models. McGowin and colleagues demonstrated that the organism can attach to reproductive tract epithelial cells and elicits cellular immune responses that result in inflammation (65, 66). In another *in vitro* organ culture model, *M. genitalium* adhered to human fallopian tube epithelium after experimental inoculation, causing swelling of the cilia and detachment of cilia from the epithelium (67). Svenstrup and colleagues also investigated whether mobile sperm could serve as a vector for transmitting *M. genitalium* to the upper genital tract of women, demonstrating that the organism does adhere to human spermatozoa and could be transported by sperm to the uterus and fallopian tubes to colonize and destroy the ciliated epithelia (68).

When compared with the more severe damage that *C. trachomatis* and *N. gonorrhoeae* infection create in the fallopian tube, the damage caused by *M. genitalium* tends to be moderate (65). However, when left untreated, damage may accumulate and yield serious long-term sequelae on fallopian tube function. Additionally, simultaneous infection with *M. genitalium* and other sexually transmitted bacteria may cause even more severe tubal pathology. One study conducted in Saudi Arabia used PCR performed on tubal samples from women with ectopic pregnancy and compared them to samples from fertile women undergoing partial salpingectomy for sterilization or at the time of hysterectomy (69). They found a 6-fold higher rate of infection with *C. trachomatis* and *M. genitalium* in women with ectopic pregnancy compared to the controls. There was also a higher rate of other infections, including *U. urealyticum/parvum*, *G. vaginalis*, *N. gonorrhoeae*, and *T. vaginalis*, but these

associations were not statistically significant. The investigators noted that co-infection with at least 2 organisms led to a 5-fold increase in the risk of ectopic pregnancy, providing further evidence that multiple infections leads to greater risk of tubal damage (69).

Animal studies have also been performed to investigate the potential role of *M. genitalium* on tubal scarring and inflammation. Female grivet monkeys and marmosets inoculated with *M. genitalium* developed severe endosalpingitis, along with luminal exudates and adhesions between mucosal folds in the fallopian tubes, similar to changes induced by chlamydial infection (70). Additionally, female Swiss Webster mice developed upper reproductive tract infection as early as 3 days after being inoculated with *M. genitalium*, showing experimentally that *M. genitalium* is capable not only of ascending through the upper genital tract, but persistently colonizing reproductive tract tissues that could lead to long-term tubal inflammation and occlusion (71).

Both serological and epidemiological studies have explored whether *M. genitalium* is associated with clinical PID and salpingitis. In an analysis of 193 patients with clinically-diagnosed PID and 246 healthy pregnant controls, 17% were *M. genitalium* seropositive, although the association was not statistically significant after adjusting for age and presence of antibodies to *C. trachomatis* (72). An older study by Møller and colleagues also showed an association; in a group of patients with acute PID without *C. trachomatis* antibodies, almost 40% had a four-fold or greater change in the titre of *Mycoplasma genitalium* antibodies (73). Still, results are conflicting, as Lind and colleagues assessed the significance of antibodies to *M. genitalium* in patients with acute salpingitis and failed to confirm any association (74).

Recent studies have examined the relationship between current cervical or endometrial *M. genitalium* infection and upper genital tract infection (74-78). In an analysis of 586 women who participated in the PID Evaluation and Clinical Health (PEACH) Study, a randomized multicenter clinical trial in the United States, 31% of women who tested positive for *M. genitalium* in the endometrium reported recurrent PID, 42% had chronic pelvic pain, and 22% were infertile (75). However, a large prospective trial of 2378 young women in London failed to show an association between *M. genitalium* and acute PID. Among women with *M. genitalium* at baseline, 3.9% developed PID after 12 months compared with 1.7% of women without baseline infection; however, this difference was not statistically significant (66). Oakeshott and colleagues concluded that because the population attributable risk of PID due to *M. genitalium* was only 4%, *M. genitalium* infection is not an important risk factor for pelvic inflammation (79). This particular European population may not be generalizable to populations with higher prevalence rates of *M. genitalium* infection, where, if confirmed, this two-fold increased risk of PID due to *M. genitalium* infection could constitute a major public health problem (75). Still, while evidence shows that *M. genitalium* is often present in or associated with PID cases, more data is necessary to determine the role of this microorganism in the pathogenesis of PID and subsequent TFI.

M. genitalium may not only affect tubal patency; several studies have investigated its effects on pregnancy outcomes such as ectopic pregnancy, recurrent pregnancy loss, and preterm birth. However, unlike for *C. trachomatis*, there is limited evidence that the pathogen is

associated with these adverse pregnancy outcomes. A serological case-control study by Jurstrand and coworkers showed no significant correlation between *M. genitalium* antibodies and ectopic pregnancy (80). According to a recent meta-analysis, *M. genitalium* infection has been shown to be significantly associated with increased risk of both spontaneous abortion and preterm birth in some studies, although evidence is inconsistent (81). While data is emerging on the impact of *M. genitalium* on the reproductive health of women, further research is necessary to solidify any conclusions regarding *M. genitalium* and adverse pregnancy outcomes.

Trichomonas vaginalis

Like that of *M. genitalium*, the role of *Trichomonas vaginalis* infection in reproductive tract pathology has been understudied, but investigators have shown that it may be associated with female infertility. *T. vaginalis* is the most common non-viral, sexually transmitted pathogen in the United States. According to the World Health Organization, the protozoan *T. vaginalis* accounts for more than half of all curable STDs worldwide (82). An estimated 7.4 million new infections occur annually in the U.S. (83) and approximately 3.1% of reproductive-age women are infected (84). Given the high prevalence of *T. vaginalis* in the population, any potential impact of the organism on the upper reproductive tract could constitute a serious public health concern.

Data associating *T. vaginalis* with TFI and pelvic inflammation in the literature is relatively weak. Few retrospective studies have found that women with self-reported infertility were 2-3 times more likely to have a current *T. vaginalis* infection, and women with a self-reported history of a *T. vaginalis* infection have approximately a two-fold risk of tubal infertility (45, 84-88). Additionally, a trend exists between increasing number of episodes of *T. vaginalis* infection and increasing risk of infertility (45). However, many of the epidemiologic studies analyzing the association between trichomoniasis and infertility failed to control for important confounding variables such as presence or history of other reproductive tract infections.

Upon investigation of endometrial inflammatory changes elicited by infections, immunohistochemical evidence shows that *T. vaginalis* may contribute to upper genital tract inflammation (89). Pathologically, *T. vaginalis* has been shown to be capable of ascending the upper genital tract and has been associated with up to 30% of acute salpingitis cases, although within the same study, trichomonads were not demonstrated in tubal cultures from cases of salpingitis (90). *T. vaginalis* has been shown to be associated clinically with endometritis, salpingitis, and atypical PID (91-94), demonstrating that it may be an important pathogen in upper genital tract damage. Other potential mechanisms linking *T. vaginalis* infection to infertility include disruption of sperm motility (93), phagocytosis of sperm, and transportation of other infectious agents to the upper genital tract by motile trichomonads (86, 87), although these mechanisms do not directly affect the female reproductive tract.

Co-infection of *T. vaginalis* and *C. trachomatis* may increase the risk of upper genital tract infection more than the risk of *C. trachomatis* infection alone, and women with both *T. vaginalis* and HIV-1 have been shown to have a significantly higher risk of PID than women

without *T. vaginalis* (87, 94). Because trichomonads are capable of phagocytizing bacteria, yeast, vaginal epithelial cells, mycoplasmas, and herpesviruses *in vitro* (96-99), investigators speculate that *T. vaginalis* infection may be capable of spreading other pathogens throughout the upper genital tract, thereby indirectly eliciting tubal damage and infertility. Moreover, despite some of these weak associations, proposed mechanisms, and possible co-infection risks, there is currently no strong conclusive evidence regarding the causative effects of *T. vaginalis* on PID or infertility.

Vaginal Microbiome and Other Potential Pathogens

N. gonorrhoeae, *C. trachomatis*, and *M. genitalium* may not be the only organisms capable of damaging the reproductive tract. Both *Mycoplasma hominis* and *Ureaplasma urealyticum*, two common species of genital mycoplasma, have been investigated as possible causative agents for infertility and pelvic inflammation. *M. hominis* is commonly found in the upper genital tract. The adverse influence of *M. hominis* on the female reproductive tract was identified in 1976 by Mårdh and colleagues, as they demonstrated with *in vitro* organ cultures the swelling of the ciliated tubal epithelial cells due to *M. hominis* infection (100). The organism has been isolated from the fallopian tubes of women with a history of infertility and laparoscopically-confirmed salpingitis, although recent data have not necessarily reproduced these findings (62, 90, 101, 102).

Ureaplasmas, including *U. urealyticum*, have also been investigated as potential culprits of female infertility. Like *M. hominis*, ureaplasmas have been isolated from the fallopian tubes of patients with PID, yet their presence in patients with PID is rare (90, 103). Some studies suggest a causal relationship between *U. urealyticum* and infertility, but most controlled studies do not confirm such a pathogenic role. Evidence supporting both *M. hominis* and *U. urealyticum* as agents involved in infertility is not nearly as conclusive as existing evidence for pathogens such as *C. trachomatis* and *N. gonorrhoeae*; while some investigators have been able to detect each of the organisms in infertile patients and in patients with upper genital tract disorders, several have not shown any correlation (103-106). As with *T. vaginalis*, the existing evidence for *M. hominis* and ureaplasmas as pathogens causing infertility is therefore not sufficiently definitive.

While the focus of this review was to identify sexually transmitted pathogens that affect fertility, other infectious diseases are important to consider in discussing infertility. In the developing world where exposure to *Mycobacterium tuberculosis* is common, genital tuberculosis (GTB) is a significant cause of infertility. Though its incidence is less than 1% in industrialized countries, GTB rates can be as high as 13% in developing countries, eliciting a major public health concern (107). In almost all cases of GTB, *Mycobacterium tuberculosis* spreads hematogenously from a primary source, most commonly the lungs, to the fallopian tubes, producing irreversible tubal damage and ultimately leading to TFI in up to 40% of cases (1). In addition to infertility, GTB has also been shown to be an important risk factor for ectopic pregnancy in developing countries (108, 109). The silent nature of GTB, which often persists without any clinical manifestations, allows development of fulminating infection without detection (110). Early detection and treatment of GTB is vital

to improve reproductive outcomes, but unfortunately provides no benefit to reverse tubal damage once the disease is advanced (111).

Rather than a single organism impairing female fertility, variations in the overall vaginal microbiome, such as in bacterial vaginosis, may also have a role in infertility (112). A recent meta-analysis exploring the role of bacterial vaginosis (BV) on infertility has shown that BV is significantly more prevalent in infertile women than in pregnant women of the same population (113). According to this systematic review of 12 studies reporting the prevalence of BV in patients with infertility of all subtypes, an estimated one in five infertile women has BV, and at least one in three has an abnormal vaginal microflora. Four studies have shown that BV is significantly more prevalent in women with tubal infertility than in women with non-tubal infertility (114-117), including a recent study among Nigerian women that demonstrated that BV was four times more prevalent in women with TFI compared to fertile controls (117). Additionally, after adjusting for several factors, including current infection with *N. gonorrhoeae*, *C. trachomatis*, or *T. vaginalis*, BV has been linked to laparoscopically-confirmed PID, endometritis, and salpingitis (114, 118-121), suggesting that the effects of BV are not confined to the lower genital tract and may therefore interfere with female fertility. In fact, microorganisms that are highly prevalent in the vagina among women with BV have been recovered in the fallopian tubes of women with laparoscopically-confirmed PID and acute salpingitis (122).

However, the role of BV in infertility and in upper genital tract morbidity is still not completely clear, as other studies refute any significant correlation (123). Likewise, the studies that do show correlations between BV and tubal pathology do not necessarily help distinguish whether this finding is secondary to previous tubal damage caused by infections such as *C. trachomatis* and *N. gonorrhoeae*, or whether BV infection may help spread these infections to the upper genital tract (116). It is uncertain whether or not BV itself is the direct cause of damage on the fallopian tubes, but given its high prevalence among women with TFI, alongside the high percentage of women with BV that remain undiagnosed and untreated, further investigations elucidating the role of anaerobic overgrowth, biofilms, and the vaginal microbiome are needed (117).

Conclusions

In summary, the totality of the evidence linking *N. gonorrhoeae* and *C. trachomatis* to infertility is compelling. However, the associations found between *M. genitalium*, *T. vaginalis* and other potential pathogens are suggestive, but far from definitive. Additional research is necessary to strengthen the suggestions that *M. genitalium* and *T. vaginalis* can cause infertility. We would recommend additional serological studies in a diverse sample of reproductive age women while controlling for the history of other STDs. Prospective studies assessing demographic and behavioral factors, the impacts of co-infections, and the impact of the vaginal microbiome are needed to sort out the relationship between these pathogens and impaired fertility and adverse pregnancy outcomes.

Nonetheless, for those pathogens where reproductive tract pathology is evident, screening and treatment should be emphasized in the clinical setting. The literature regarding the

importance and benefit of treating these pathogens to enhance fertility on the population level is sparse, although a recent study in Washington observed a potential association between disease management trends and reduction of reproductive morbidities (53). While further investigations are necessary to establish a tangible benefit, it is nonetheless well-understood that women who delay seeking care for what is often an asymptomatic infection have a higher risk for infertility and other reproductive morbidities. The U. S. Preventive Services Task Force has issued chlamydia and gonorrhea screening recommendations since 2000 to reduce associated morbidities (124), but such guidelines regarding other non-traditional pathogens have not been established. Future research to evaluate the impact of screening and treatment programs for non-traditional pathogens such as *Mycoplasma genitalium* and other organisms in the microbiome should be considered to help guide clinical practice and health policy to more effectively reduce the global burden of infertility.

Acknowledgments

Financial disclaimer: Dr. Peipert receives research support from Bayer, Merck, and Teva, and serves on Advisory Boards for Teva and Perrigo.

References

1. Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. *Hum Reprod*. 2007; 22(6):1506–12. [PubMed: 17376819]
2. Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United States, 1982–2010: data from the National Survey of Family Growth. *National health statistics reports*. 2013; 67:1–19.
3. Inhorn M, P P. Infertility around the globe: new thinking on gender, reproductive technologies, and global movement in the 21st century. *Human Reproductive Update*. 2015; 21(4):411–26.
4. Cousineau TMD, Alice D. Psychological impact of infertility. *Clin Obstet Gynecol*. 2006; 21(2): 293–308.
5. Ezeh A, Bankole A, Cleland J, García-Moreno C, Temmerman M, Ziraba AK. Burden of Reproductive Ill Health. *Reproductive, Maternal, Newborn, and Child Health: Disease Control Priorities*. Apr.2016 11:25.
6. Daar AS, Merali Z. Infertility and social suffering: the case of ART in developing countries. *Current practices and controversies in assisted reproduction*. 2002:15–21.
7. Quaas A, Dokras A. Diagnosis and Treatment of Unexplained Infertility. *Rev Obstet Gynecol*. 2008; 1(2):69–76. [PubMed: 18769664]
8. US Department of Health and Human Services. 2004 Assisted Reproductive Technology Success Rates: National summary and Fertility Clinic Reports. 2006
9. Wiesenfeld, HC.; Cates, W, Jr. Sexually Transmitted Diseases and Infertility.. In: Holmes, KKSP.; Stamm, WE.; Piot, P.; Wasserheit, JN.; Corey, L.; Cohen, MS.; Watts, DH., editors. *Sexually Transmitted Diseases*. Vol. 4. McGraw Hill; 2008. p. 1511–29.
10. Khanum S, Ahmed J, Rahim M, Sultana N, Begum R. Evidence Based Diagnostic Approach to Tubal Factor Infertility. *BIRDEM Med J*. 2014; 4(1):33–7.
11. Ross JDC. Pelvic inflammatory disease. *Medicine*. 2014; 42(6):333–7.
12. Westrom L. Effect of pelvic inflammatory disease on fertility. *Venereology: official publication of the National Venereology Council of Australia*. 1995; 8(4):219–22. [PubMed: 12291198]
13. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory disease and infertility. *Obstet Gynecol*. 2012; 120(1):37–43. [PubMed: 22678036]
14. Noeggerath E. Latent gonorrhea, especially with regard to its influence on fertility in women. *Am J Obstet Gynecol*. 1951; 62(4):726–31.

15. Cates W, Rolfs RT, ARAL SO. Sexually transmitted diseases, pelvic inflammatory disease, and infertility: an epidemiologic update. *Epidemiol Rev.* 1990; 12(1):199–220. [PubMed: 2126772]
16. Bowen E. Limits of the Lab: Diagnosing “Latent Gonorrhea,” 1872–1910. *Bull Hist Med.* 2013; 87(1):63–85. [PubMed: 23603529]
17. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance. U.S. Department of Health and Human Services; Atlanta, GA: Nov. 2008 2009
18. Nelson HD, Zakher B, Cantor A, Deagas M, Pappas M. Screening for Gonorrhea and Chlamydia: Systematic Review to Update the US Preventive Services Task Force Recommendations. 2014
19. Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. *MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control.* 2014; 63:1.
20. Linhares IM, Witkin SS. Immunopathogenic consequences of Chlamydia trachomatis 60 kDa heat shock protein expression in the female reproductive tract. *Cell Stress Chaperones.* 2010; 15(5): 467–73. [PubMed: 20182835]
21. Mårdh P-A. Tubal factor infertility, with special regard to chlamydial salpingitis. *Curr Opin Infect Dis.* 2004; 17(1):49–52. [PubMed: 15090891]
22. Akande VA, Hunt LP, Cahill DJ, Caul EO, Ford WCL, Jenkins JM. Tubal damage in infertile women: prediction using chlamydia serology. *Hum Reprod.* 2003; 18(9):1841–7. [PubMed: 12923136]
23. Clausen HF, Fedder J, Drasbek M, Nielsen PK, Toft B, Ingerslev HJ, et al. Serological investigation of Mycoplasma genitalium in infertile women. *Hum Reprod.* 2001; 16(9):1866–74. [PubMed: 11527890]
24. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility—a prospective study. *Fertil Steril.* 2008; 90(3):513–20. [PubMed: 17548070]
25. Veenemans L, Van der Linden P. The value of Chlamydia trachomatis antibody testing in predicting tubal factor infertility. *Hum Reprod.* 2002; 17(3):695–8. [PubMed: 11870122]
26. Meikle S, Zhang X, Marine W, Calonge B, Hamman R, Betz G. Chlamydia trachomatis antibody titers and hysterosalpingography in predicting tubal disease in infertility patients. *Fertil Steril.* 1994; 62(2):305–12. [PubMed: 8034077]
27. Den Hartog J, Land J, Stassen F, Kessels A, Bruggeman C. Serological markers of persistent C. trachomatis infections in women with tubal factor subfertility. *Hum Reprod.* 2005; 20(4):986–90. [PubMed: 15640255]
28. Coppus S, Land J, Opmeer B, Steures P, Eijkemans M, Hompes P, et al. Chlamydia trachomatis IgG seropositivity is associated with lower natural conception rates in ovulatory subfertile women without visible tubal pathology. *Hum Reprod.* 2011; 26(11):3061–7. [PubMed: 21926058]
29. Thomas K, Coughlin L, Mannion P, Haddad N. The value of Chlamydia trachomatis antibody testing as part of routine infertility investigations. *Hum Reprod.* 2000; 15(5):1079–82. [PubMed: 10783356]
30. Weström L. Pelvic inflammatory disease: bacteriology and sequelae. *Contraception.* 1987; 36(1): 111–28. [PubMed: 3311621]
31. Mol B, Lijmer JG, Ankum WM, van der Veen F, Bossuyt P. The accuracy of single serum progesterone measurement in the diagnosis of ectopic pregnancy: a meta-analysis. *Hum Reprod.* 1998; 13(11):3220–7. [PubMed: 9853884]
32. Cates W, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. *Am J Obstet Gynecol.* 1991; 164(6):1771–81. [PubMed: 2039031]
33. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. *J Infect Dis.* 2010; 201(Supplement 2):S134–S55. [PubMed: 20470050]
34. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. *Sex Trans Dis.* 1992; 19(4):185–92.

35. Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amortegui AJ, Hillier SL. Comparison of acute and subclinical pelvic inflammatory disease. *Sex Trans Dis*. 2005; 32(7):400–5.
36. Mol BW, Dijkman B, Wertheim P, Lijmer J, van der Veen F, Bossuyt PM. The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis. *Fertil Steril*. Jun. 1997; 67(6):1031–7. [PubMed: 9176440]
37. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, Hook EW 3rd, Morrison RP. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. *J Infect Dis*. Dec 15; 2012 206(12):1836–43. [PubMed: 23045619]
38. Feinberg EC. Expanding the scope of the basic infertility workup. *Fertil Steril*. 2015; 104(6):1379. [PubMed: 26453268]
39. Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. *Fertil Steril*. Dec. 2015; 104(6):1522–6. [PubMed: 26413816]
40. Collins AM, Jackson KJ. A temporal model of human IgE and IgG antibody function. *Front Immunol*. 2013; 4:235. [PubMed: 23950757]
41. Coppus SF, Land JA, Opmeer BC, Steures P, Eijkemans MJ, Hompes PG, Bossuyt PM, van der Veen F, Mol BW, van der Steeg JW. Chlamydia trachomatis IgG seropositivity is associated with lower natural conception rates in ovulatory subfertile women without visible tubal pathology. *Hum Reprod*. Nov; 2011 26(11):3061–7. [PubMed: 21926058]
42. Neuer A, Spandorfer SD, Giraldo P, Dieterle S, Rosenwaks Z, Witkin SS. The role of heat shock proteins in reproduction. *Hum Reprod Update*. 2000; 6:149–159. [PubMed: 10782573]
43. Stephens AJ, Aubuchon M, Schust DJ. Antichlamydial antibodies, human fertility, and pregnancy wastage. *Infect Dis Obstet Gynecol*. 2011; 2011:525182. [PubMed: 21949601]
44. Swasdio K, Rugsapao S, Tansathit T, Uttavichai C, Jongusuk P, Vutayavanich T, et al. The association of Chlamydia trachomatis/gonococcal infection and tubal factor infertility. *J Obstet Gynaecol Res*. 1996; 22(4):331–40. [PubMed: 8870415]
45. Grodstein F, Goldman MB, Cramer DW. Relation of tubal infertility to history of sexually transmitted diseases. *Am J Epidemiol*. 1993; 137(5):577–84. [PubMed: 8465809]
46. Robertson J, Ward M, Conway D, Caul E. Chlamydial and gonococcal antibodies in sera of infertile women with tubal obstruction. *J Clin Path*. 1987; 40(4):377–83. [PubMed: 3108327]
47. Miettinen A, Heinonen PK, Teisala K, Hakkarainen K, Punnonen R. Serologic evidence for the role of Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma hominis in the etiology of tubal factor infertility and ectopic pregnancy. *Sex Trans Dis*. 1990; 17(1):10.
48. World Health Organization. Task force on the prevention and management of infertility. Tubal infertility: Serologic relationship to past chlamydial and gonococcal infection. *Sex Transm Dis*. 1995; 22:71–7. [PubMed: 7624815]
49. Safrin S, Schachter J, Dahrouge D, Sweet RL. Long-term sequelae of acute pelvic inflammatory disease: a retrospective cohort study. *Am J Obstet Gynecol*. 1992; 166(4):1300–5.
50. Hillis SD, Joesoef R, Marchbanks PA, Wasserheit JN, Cates W, Westrom L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. *Am J Obstet Gynecol*. 1993; 168(5): 1503–9.
51. Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. *Hum Reprod Update*. 1999; 5(5):433–47. [PubMed: 10582782]
52. Short VLTP, Ness RB, Astete SG, Kelsey SF, Haggerty CL. Clinical Presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae Infection among Women with Pelvic Inflammatory Disease. *Clin Infect Dis*. 2009; 48(1):41–7. [PubMed: 19025498]
53. Moore MS, Golden MR, Scholes D, Kerani RP. Assessing Trends in Chlamydia Positivity and Gonorrhea Incidence and Their Associations With the Incidence of Pelvic Inflammatory Disease and Ectopic Pregnancy in Washington State, 1988–2010. *Sex Transm Dis*. 2016; 43(1):2–8. [PubMed: 26656441]

54. Manhart LE, Holmes KK, Hughes JP, Houston LS, Totten PA. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. *Am J Public Health.* 2007; 97(6):1118. [PubMed: 17463380]
55. Haggerty CL. Evidence for a role of Mycoplasma genitalium in pelvic inflammatory disease. *Curr Opin Infect Dis.* 2008; 21(1):65–9. [PubMed: 18192788]
56. Palmer HM, Gilroy CB, Furr PM, Taylor-Robinson D. Development and evaluation of the polymerase chain reaction to detect Mycoplasma genitalium. *FEMS Microbiol Lett.* 1991; 61(2-3): 199–203. [PubMed: 2037229]
57. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Hobbs MM. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. *Sex Trans Dis.* 2008; 35(3)
58. Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, Fleischmann RD, et al. The minimal gene complement of Mycoplasma genitalium. *Science.* 1995; 270(5235):397–404. [PubMed: 7569993]
59. Tully J, Cole R, Taylor-Robinson D, Rose D. A newly discovered mycoplasma in the human urogenital tract. *The Lancet.* 1981; 317(8233):1288–91.
60. Manhart L, Broad J, Golden M. Mycoplasma genitalium: Should We Treat and How? *Clin Infect Dis.* 2011; 53(3):S129–S42. [PubMed: 22080266]
61. Idahl AJM, Olofsson JI, Fredlund H. Mycoplasma genitalium serum antibodies in infertile couples and fertile women. *Sex Transm Infect.* 2015; 10(1136):1–3.
62. Møller B, Taylor-Robinson D, Furr PM, Toft B, Allen J. Serological evidence that chlamydiae and mycoplasmas are involved in infertility of women. *J Reprod Fertil.* 1985; 73(1):237–40. [PubMed: 3881583]
63. Grze ko J, Elias M, M czy ska B, Kasprzykowska U, Tłaczała M, Goluda M. Occurrence of Mycoplasma genitalium in fertile and infertile women. *Fertil Steril.* 2009; 91(6):2376–80. [PubMed: 18571169]
64. Moghadam NM, Kheirkhah B, Mirshekari TR, Harandi MF, Tafsiri E. Isolation and molecular identification of mycoplasma genitalium from the secretion of genital tract in infertile male and female. *Iranian Journal of Reproductive Medicine.* 2014; 12(9):601. [PubMed: 25469132]
65. McGowin CL, Ma L, Martin DH, Pyles RB. Mycoplasma genitalium-encoded MG309 activates NF- κ B via Toll-like receptors 2 and 6 to elicit proinflammatory cytokine secretion from human genital epithelial cells. *Infect Immun.* 2009; 77(3):1175–81. [PubMed: 19103762]
66. McGowin CL, Popov VL, Pyles RB. Intracellular Mycoplasma genitalium infection of human vaginal and cervical epithelial cells elicits distinct patterns of inflammatory cytokine secretion and provides a possible survival niche against macrophage-mediated killing. *BMC Microbiol.* 2009; 9(1):139. [PubMed: 19602269]
67. Baczynska A, Funch P, Fedder J, Knudsen HJ, Birkelund S, Christiansen G. Morphology of human Fallopian tubes after infection with Mycoplasma genitalium and Mycoplasma hominis—in vitro organ culture study. *Hum Reprod.* 2007; 22(4):968–79. [PubMed: 17158214]
68. Svenstrup HF, Fedder J, Abraham-Peskir J, Birkelund S, Christiansen G. Mycoplasma genitalium attaches to human spermatozoa. *Hum Reprod.* 2003; 18(10):2103–9. [PubMed: 14507829]
69. Ashshi AM, Batwa SA, Kutbi SY, Malibary FA, Batwa M, Refaat B. Prevalence of 7 sexually transmitted organisms by multiplex real-time PCR in Fallopian tube specimens collected from Saudi women with and without ectopic pregnancy. *BMC Infect Dis.* 2015; 15(1):569. [PubMed: 26666587]
70. Møller B, Taylor-Robinson D, Furr P, Freundt E. Acute upper genital-tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. *Br J Exp Pathol.* 1985; 66(4):417. [PubMed: 4027175]
71. McGowin CL, Spagnuolo RA, Pyles RB. Mycoplasma genitalium rapidly disseminates to the upper reproductive tracts and knees of female mice following vaginal inoculation. *Infect Immun.* 2010; 78(2):726–36. [PubMed: 19995897]
72. Jurstrand M, Jensen JS, Magnuson A, Kamwendo F, Fredlund H. A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy. *Sex Transm Infect.* 2007; 83(4):319–23. [PubMed: 17475688]

73. Møller B, Taylor-Robinson D, Purr P. Serological evidence implicating *Mycoplasma genitalium* in pelvic inflammatory disease. *The Lancet*. 1984; 323(8386):1102–3.
74. Lind K, Kristensen G. Significance of antibodies to *Mycoplasma genitalium* in salpingitis. *Eur J Clin Microbiol Infect Dis*. 1987; 6(2):205–7.
75. Haggerty CL, Totten PA, Astete SG, Lee S, Hoferka SL, Kelsey SF, et al. Failure of cefoxitin and doxycycline to eradicate endometrial *Mycoplasma genitalium* and the consequence for clinical cure of pelvic inflammatory disease. *Sex Trans Infect*. 2008; 84(5):338–42.
76. Simms I, Eastick K, Mallinson H, Thomas K, Gokhale R, Hay P, et al. Associations between *Mycoplasma genitalium*, *Chlamydia trachomatis* and pelvic inflammatory disease. *J Clin Pathol*. 2003; 56(8):616–8. [PubMed: 12890814]
77. Bjartling C, Osseer S, Persson K. The association between *Mycoplasma genitalium* and pelvic inflammatory disease after termination of pregnancy. *BJOG*. 2010; 117(3):361–4. [PubMed: 20015303]
78. Cohen C, Mugo N, Astete S, Odondo R, Manhart L, Kiehlbauch J, et al. Detection of *Mycoplasma genitalium* in women with laparoscopically diagnosed acute salpingitis. *Sex Trans Infect*. 2005; 81(6):463–6.
79. Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, et al. Is *Mycoplasma genitalium* in women the “New Chlamydia?” A community-based prospective cohort study. *Clin Infect Dis*. 2010; 51(10):1160–6. [PubMed: 20942656]
80. Jurstrand M, Jensen JS, Magnuson A, Kamwendo F, Fredlund H. A serological study of the role of *Mycoplasma genitalium* in pelvic inflammatory disease and ectopic pregnancy. *Sex Transm Infect*. Jul. 2007; 83(4):319–2. [PubMed: 17475688]
81. Lis R, Rowhani-Rahbar A, Manhart LE. *Mycoplasma genitalium* infection and female reproductive tract disease: a meta-analysis. *Clin Infect Dis*. Aug 1; 2015 61(3):418–26. [PubMed: 25900174]
82. World Health Organization. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections. WHO; Geneva: 2001.
83. Coleman JS, Gaydos CA, Witter F. *Trichomonas vaginalis* vaginitis in obstetrics and gynecology practice: new concepts and controversies. *Obstet Gynecol Surv*. 2013; 68(1):43. [PubMed: 23322080]
84. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MCB, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. *Sex Trans Dis*. 2013; 40(3):187–93.
85. Klinger EV, Kapiga SH, Sam NE, Aboud S, Chen C-Y, Ballard RC, et al. A Community-based study of risk factors for *Trichomonas vaginalis* infection among women and their male partners in Moshi urban district, northern Tanzania. *Sex Trans Dis*. 2006; 33(12):712–8.
86. Passey M, Mgone C, Lupiwa S, Suve N, Tiwara S, Lupiwa T, et al. Community based study of sexually transmitted diseases in rural women in the highlands of Papua New Guinea: prevalence and risk factors. *Sex Trans Infect*. 1998; 74(2):120–7.
87. Sherman KJ, Daling JR, Weiss NS. Sexually transmitted diseases and tubal infertility. *Sex Trans Dis*. 1987; 14(1):12–6.
88. El-Shazly AM, El-Naggar HM, Soliman M, El-Negeri M, El-Nemr HE, Handousa AE, et al. A study on *Trichomoniasis vaginalis* and female infertility. *J Egypt Soc Parasitol*. 2001; 31(2):545–53. [PubMed: 11478453]
89. Reighard SD, Sweet RL, Vicetti Miguel C, Vicetti Miguel RD, Chivukula M, Krishnamurti U, et al. Endometrial leukocyte subpopulations associated with *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* genital tract infection. *Am J Obstet Gynecol*. 2011; 205(4):324, e1–7. [PubMed: 21777898]
90. Mårdh P, Weström L. Tubal and cervical cultures in acute salpingitis with special reference to *Mycoplasma hominis* and T-strain mycoplasmas. *Br J Vener Dis*. 1970; 46(3):179–86. [PubMed: 4988097]
91. Cherpes TL, Wiesenfeld HC, Melan MA, Kant JA, Cosentino LA, Meyn LA, et al. The associations between pelvic inflammatory disease, *Trichomonas vaginalis* infection, and positive herpes simplex virus type 2 serology. *Sex Trans Dis*. 2006; 33(12):747–52.

92. Cates W, Joesoef MR, Goldman MB. Atypical pelvic inflammatory disease: can we identify clinical predictors? *Am J Obstet Gynecol.* 1993; 169(2):341–6. [PubMed: 8362945]
93. Hoosen A, Quinlan D, Moodley J, Kharsany A, Van den Ende J. Sexually transmitted pathogens in acute pelvic inflammatory disease. *S Afr Med J.* 1989; 76(6):251–4. [PubMed: 2506653]
94. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. *Trichomonas vaginalis* is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. *Clin Infect Dis.* 2002; 34(4):519–22. [PubMed: 11797180]
95. Wiwanitkit V. Counteraction during movement of spermatozoa by *Trichomonas vaginalis* observed by visual image analysis: a possible cause of female infertility. *Fertil Steril.* 2008; 90(3):528–30. [PubMed: 17953953]
96. Pindak F, De Pindak MM, Hyde B, Gardner W. Acquisition and retention of viruses by *Trichomonas vaginalis*. *Genitourin Med.* 1989; 65(6):366–71. [PubMed: 2559023]
97. Scholtyseck E, Teras J, Kasakova I, Sethi K. Electron microscope observations on the interaction of *Mycoplasma fermentans* with *Trichomonas vaginalis*. *Zeitschrift für Parasitenkunde.* 1985; 71(4):435–42. [PubMed: 3895766]
98. Francioli P, Shio H, Roberts RB, Müller M. Phagocytosis and killing of *Neisseria gonorrhoeae* by *Trichomonas vaginalis*. *J Infect Dis.* 1983; 147(1):87–94. [PubMed: 6401789]
99. Hardy P, Nell EE, Spence M, Hardy J, Graham D, Rosenbaum R. Prevalence of six sexually transmitted disease agents among pregnant inner-city adolescents and pregnancy outcome. *The Lancet.* 1984; 324(8398):333–7.
100. Mårdh P, Weström L, von Mecklenburg C, Hammar E. Studies on ciliated epithelia of the human genital tract. I. Swelling of the cilia of Fallopian tube epithelium in organ cultures infected with *Mycoplasma hominis*. *Br J Vener Dis.* 1976; 52(1):52–7. [PubMed: 1260408]
101. Mårdh P, Weström L. Antibodies to *Mycoplasma hominis* in patients with genital infections and in healthy controls. *Br J Vener Dis.* 1970; 46(5):390–7. [PubMed: 5536333]
102. Farzand, JKaR. Prevalence of *Mycoplasma hominis* and *Ureaplasma urealyticum* among women with unexplained infertility, with and without vaginitis and cervicitis. *Afr J Microbiol Res.* 2011; 5(8):861–4.
103. Sweet RL. Colonization of the endometrium and fallopian tubes with *Ureaplasma urealyticum*. *Pediatr Infect Dis J.* 1986; 5(6):S244–S6.
104. Baczynska A, Svenstrup HF, Fedder J, Birkelund S, Christiansen G. The use of enzyme-linked immunosorbent assay for detection of *Mycoplasma hominis* antibodies in infertile women serum samples. *Hum Reprod.* 2005; 20(5):1277–85. [PubMed: 15734761]
105. Tyagi P. Mycoplasmal antibodies as determined with an enzymelinked immunosorbent assay, in tubal factor infertility. *Ind J Med Sci.* 1999; 53(11):481.
106. Totten, PAT-RD.; Jensen, JS. Genital Mycoplasmas.. In: Holmes, KKSP.; Stamm, WE., editors. Sexually Transmitted Diseases. editor. Sexually Transmitted Diseases. Vol. 4. McGraw Hill; New York: 2008. p. 709-36.
107. Eftekhar M, Pourmasumi S, Sabeti P, Aflatoonian A, Sheikhha MH. Mycobacterium tuberculosis infection in women with unexplained infertility. *Int J Reprod Biomed (Yazd).* Dec; 2015 13(12): 749–754. [PubMed: 27141534]
108. Banerjee A, Prateek S, Malik S, Dhingra D. Genital tuberculosis in adolescent girls from low socioeconomic status with acute ectopic pregnancy presenting at a tertiary care hospital in urban Northern India: are we missing an opportunity to treat? *Arch Gynecol Obstet.* Dec. 2012; 286(6): 1477–82. [PubMed: 22872027]
109. Sharma JB, Naha M, Kumar S, Roy KK, Singh N, Arora R. Genital tuberculosis: an important cause of ectopic pregnancy in India. *Indian J Tuberc.* Oct. 2014; 61(4):312–7. [PubMed: 25675694]
110. Al eryani AA, Abdelrub AS, Al Harazi AH. Genital tuberculosis is common among females with tubal factor infertility: Observational study. *Alexandria J Med.* Dec; 2015 51(4):321–324.
111. Sharma JB, Sneha J, Singh JB, Kumar S, Roy KK, Singh N, Dharmendra S, Vanamail P. Comparative Study of Laparoscopic Abdominopelvic and Fallopian Tube Findings Before and After Antitubercular Therapy in Female Genital Tuberculosis With Infertility. *J Min Inv Gyn.* 2016; 23(2):215–22.

112. Sirota I, Zarek SM, Segars JH. Potential influence of the microbiome on infertility and assisted reproductive technology. *Seminars in reproductive medicine*. 2014 NIH Public Access.
113. van Oostrum N, De Sutter P, Meys J, Verstraelen H. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. *Hum Reprod*. 2013;det096.
114. Gaudoin M, Rekha P, Morris A, Lynch J, Acharya U. Bacterial vaginosis and past chlamydial infection are strongly and independently associated with tubal infertility but do not affect in vitro fertilization success rates. *Fertil Steril*. 1999; 72(4):730–2. [PubMed: 10521119]
115. Liversedge NH, Turner A, Horner PJ, Keay SD, Jenkins JM, Hull MG. The influence of bacterial vaginosis on in-vitro fertilization and embryo implantation during assisted reproduction treatment. *Hum Reprod*. 1999; 14(9):2411–5. [PubMed: 10469722]
116. Wilson JD, Ralph SG, Rutherford AJ. Rates of bacterial vaginosis in women undergoing in vitro fertilisation for different types of infertility. *BJOG*. 2002; 109(6):714–7. [PubMed: 12118653]
117. Durugbo I, Nyengidiki T, Bassey G, Wariso K. Bacterial vaginosis among women with tubal factor infertility in Nigeria. *Int J Obstet Gynecol*. 2015; 131(2):133–6.
118. Hillier SL, Kiviat NB, Hawes SE, Hasselquist MB, Hanssen PW, Eschenbach DA, et al. Role of bacterial vaginosis-associated microorganisms in endometritis. *Am J Obstet Gynecol*. 1996; 175(2):435–41. [PubMed: 8765265]
119. Peipert JF, Montano AB, Cooper AS, Sung CJ. Bacterial vaginosis as a risk factor for upper genital tract infection. *Am J Obstet Gynecol*. 1997; 177(5):1184–7. [PubMed: 9396917]
120. Wiesenfeld HC, Hillier SL, Krohn MA, Amortegui AJ, Heine RP, Landers DV, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. *Obstet Gynecol*. 2002; 100(3):456–63. [PubMed: 12220764]
121. Mania-Pramanik J, Kerkar S, Salvi V. Bacterial vaginosis: a cause of infertility? *Int J STD AIDS*. 2009; 20(11):778–81. [PubMed: 19833694]
122. Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. *Am J Obstet Gynecol*. 1994; 170(4):1008–14. discussion 14-7. Epub 1994/04/01. PubMed PMID: 8166184. [PubMed: 8166184]
123. Taylor BD, Darville T, Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease? *Sex Transm Dis*. 2013; 40(2):117–22. [PubMed: 23324974]
124. Meyers D, Wolff T, Gregory K, et al. USPSTF Recommendations for STI Screening. *Am Fam Physician*. 2008; 77:819–824. [PubMed: 18386598]